These findings suggest that P7 peptide suppresses bFGF-mediated OC progression by targeting the MEK/ERK pathway, supporting its potential as a novel therapeutic agent in OC.
Yang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: